SEHK:2142Biotechs
HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?
HBM Holdings (SEHK:2142) has drawn fresh attention after Harbour BioMed announced two company level developments. Investors are weighing the appointment of a new president for its metabolic franchise and a collaboration with China National Pharmaceutical Group.
See our latest analysis for HBM Holdings.
At a share price of HK$14.19, HBM Holdings has seen strong recent momentum, with a 21.8% 1 month share price return and a 17.5% year to date share price return, while the 3 year total...